NYSE:LLYPharmaceuticals
How Eli Lilly’s US$1 Billion NVIDIA AI Lab Could Reshape Growth, Margins and Pipeline (LLY)
Earlier this week, NVIDIA and Eli Lilly and Company unveiled a first-of-its-kind AI co-innovation lab in South San Francisco, committing up to US$1.00 billion over five years to fuse Lilly’s drug discovery expertise with NVIDIA’s BioNeMo platform, accelerated computing and AI infrastructure.
The collaboration’s continuous learning system, linking automated wet labs with AI-powered dry labs and digital twins of manufacturing, could materially reshape how Lilly discovers, develops and produces...